January 2024

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

Semin Arthritis Rheum 2024;65:152388 DOI: 10.1016/j.semarthrit.2024.152388 Epub ahead of print

Secukinumab efficacy regarding PROs and retention rate was comparable between axSpA and PsA patient groups when adjusted for confounders. Christiansen et al compared 6-, 12- and 24-month pain, fatigue, PGA, and HAQ PROs in axSpA and PsA patients treated with secukinumab, as well as 24-monthy retention rates in this real-world study.  

Keywords:

The Effect of Two Years of Secukinumab Treatment on Bone Metabolism in Patients with Radiographic Axial Spondyloarthritis: Results from Daily Clinical Practice

Biologics 2023;17:161–166 doi: 10.2147/BTT.S434318

Siderius, et al. found that secukinumab was associated with low spinal radiographic progression. Furthermore, bone-related outcomes and BTMs related to collagen resorption (sCTX, PINP) remained constant during the 2-year period, whereas the BTM related to mineralisation (BALP) decreased significantly.

Keywords:

Drug Survival, Effectiveness and Safety of Ixekizumab for Moderate-to-severe Psoriasis up to 5 Years

J Eur Acad Dermatol Venereol 2024;8(1):3 doi 10.1111/jdv.19682

This monocentric, retrospective clinical study by Mastorino, et al. found that ixekizumab demonstrated efficacy an safety in patients with PsA and PsO for up to five years. Being a super-responder was significantly associated with a lower rate of discontinuation, while high BMI was associated with a lower achievement of more than one PSAI measure up to Week 104.

Keywords:

The Risk Factors for Uveitis Among Psoriatic Arthritis Patients: A Population-based Cohort Study

Clin Rheumatol. 2023;43(3):1053–1061 doi: 10.1007/s10067-023-06834-y

Retrospective matched cohort study concludes that PsA is associated with increased risk of uveitis, with past uveitis and treatment with etanercept being independently associated with a higher risk of uveitis. Patients who developed uveitis were mainly treated with topical glucocorticoids.

December 2023

Rheumatoid Arthritis Disease Activity and Adverse Events in Patients Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of ORAL Surveillance

Ther Adv Musculoskelet Dis. 2023;15:1759720X231201047 doi: 10.1177/1759720X231201047

Post hoc analysis of ORAL Surveillance data highlights that active disease in RA leads to higher risk of adverse medical events, regardless of medication used.

Keywords:

MACE and VTE across Upadacitinib Clinical Trial Programmes in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

RMD Open 2023; 9(4):e003392 doi 10.1136/rmdopen-2023-003392

Rates of MACE and VTE events in patients with RA or PsA treated are consistent across 15 mg and 30 mg doses of upadacitinib, and comparable with active comparators adalimumab and MTX. Several risk factors were also identified for MACE and VTE events in patients with RA.

Keywords:

Sex-related Differences in Patient Characteristics, and Efficacy and Safety of Advanced Therapies in Randomised Clinical Trials in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis

Lancet Rheumatol 2023;5:e716–27

In this study, Eder, et al. performed a systematic literature review and meta-analysis of RCTs to assess information on participants’ characteristics and rates of American College of Rheumatology response and minimal disease activity by sex. The authors found that the biological sex of patients with PsA influences their response to advanced therapies, but the effect varies by drug class.

Keywords:

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two Phase 3 randomized trials in plaque psoriasis

Am Acad Dermatol 2023. doi: 10.1016/j.jaad.2023.11.060

This pooled analysis of the Phase 3 PSO-1 and PSO-2 trials shows that deucravacitinib has greater efficacy in treating scalp PsO than placebo and apremilast. At week 16, response rates were greater with deucravacitinib versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 and Psoriasis Scalp Severity Index. Efficacy was maintained through 52 weeks in patients who received continuous deucravacitinib treatment.

Keywords:

October 2023

Global, Regional, and National Burden of Rheumatoid Arthritis, 1990–2020, and Projections to 2050: a Systematic Analysis of the Global Burden of Disease Study 2021

Lancet Rheumatol 2023;5(10):e594–610 doi 10.1016/S2665-9913(23)00211-4

As part of the GBD 2021, the authors provide updated estimates for the global burden of RA. In 2020, approximately 17.6 million people worldwide had RA, with a 14.1% increase in prevalence since 1990. Mortality decreased by 23.8% from 1990 to 2020. The study forecasts an increase in cases to 31.7 million by 2050.

Keywords:

September 2023

Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis

ACR Open Rheumatol. 2023;5(12)632–643 doi 10.1002/acr2.11601

In this post hoc analysis by Deoodhar, et al., the authors found that tofacitinib demonstrated greater efficacy than placebo in bDMARD-naïve and TNFi-IR AS patients. They also found that safety event rates for tofacitinib therapy were numerically higher in the TNFi-IR subgroup than the bDMARD-naïve subgroup.

Keywords: